Simvastatin mediates inhibition of exosome synthesis, localization, and secretion via multicomponent interventions.
Discovery of exosomes as modulator of cellular communication has added a new dimension to our understanding of biological processes. Exosomes influence the biological systems by mediating trans-communication across tissues and cells, which has important implication for health and disease. Identification of strategies for exosome modulation may pave the way towards better understanding of exosome biology and development of novel therapeutics. In absence of well-characterized modulators of exosome biogenesis, an alternative option is to target pathways generating important exosomal components. Cholesterol represents one such essential component required for exosomal biogenesis. We initiated this study to test the hypothesis that owing to its cholesterol lowering effect, simvastatin, a HMG CoA inhibitor, might be able to alter exosome formation and secretion. Using previously established protocols for detecting secreted exosomes in biological fluids, simvastatin was tested for its effect on exosome secretion under various in-vitro and in-vivo settings. Murine model of AAI was used for further validation of our findings. Utilizing aforementioned systems, we demonstrate exosome-lowering potential of simvastatin in various in-vivo and in-vitro models, of AAI and atherosclerosis. We believe that the knowledge acquired in this study holds potential for extension to other exosome dominated pathologies and model systems.